GEN Article: Eliminating Bottlenecks in mAb Drug Discovery
Twist Biopharma screens massive antibody libraries with the Carterra LSA to discover therapeutic antibodies in just weeks.
Podcast: Tim Germann our Chief Commercial Officer Discusses how Carterra has Become an Innovator and Driving Force in Therapeutic Antibody Discovery
Nature Article: Speeding Antibody Screening for Drug Development
Advanced screening technology can dramatically accelerate the hunt for effective treatments for cancer, COVID-19 and more.
Video: Carterra has been Selected by the Gates Foundation to Help Solve the COVID-19 Pandemic
Carterra® Inc. Selected by the La Jolla Institute of Immunology to Provide Antibody Screening and Characterization for the Coronavirus Immunotherapy Consortium (CoVIC)
Biocompare Article on How Epitope Binning Streamlines Discovery and Exploits Diversity
Epitope binning screens and characterizes antibodies in one step. Studying kinetics, affinity, and epitope relationships in high throughput allows characterization of antibody libraries generated against a specific antigen through B cell cloning, phage display, or hybridoma technologies.
Carterra® Closes Financing Round for Continued Growth of the LSA™ Platform for Next Generation Antibody Discovery
Additional Resources Will Support New Product Development and Global Expansion
2019 Carterra Symposia
View the slides of the presentations from the therapeutic antibody revolution in the post genomics era symposia.
Bristol-Myers Squibb, Boehringer Ingelheim and Other Biotechnology Companies to Present Use of Carterra’s Next Generation Antibody Screening Technology at Symposia Across the US and Europe
Rapid Adoption of Carterra’s LSA™ Instrument Drives European Expansion
Carterra® Inc., the world leader in high-throughput antibody screening and characterization, announced today that they have opened a Customer Experience Center (CEC) and office in Munich, Germany. Rapid European adoption of Carterra’s platform has fueled the need for the new office.